Lenacapavir

• Target :

  HIV Protease

• Related Pathways :

  Microbiology/Virology|||Proteases/Proteasome

• Purity :

  >99.99%

• Bioactivity :

  Lenacapavir (GS-6207) is the first HIV-1 capsid inhibitor approved by the U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada for the treatment of MDR HIV-1 infection.[3]

• Smiles :

  [H][C@]12C[C@@]1([H])C(F)(F)c1c2c(nn1CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)c1nc(ccc1-c1ccc(Cl)c2c(NS(C)(=O)=O)nn(CC(F)(F)F)c12)C#CC(C)(C)S(C)(=O)=O)C(F)(F)F

• Molecular Formula :

  C39H32ClF10N7O5S2

• Molecular Weight :

  968.28

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2189684-44-2